GlassScriptPhysician profile
Cynthia S Gulick
NPI 1780756494
$2,885.93
in general payments reported to CMS, 2019-2025
34 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $352 · 2021: $702 · 2022: $512 · 2023: $457 · 2024: $212 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.49 | 2019-2024 | |
| Novo Nordisk INC | $340.51 | 2019-2025 | |
| Lilly USA, LLC | $198.55 | 2020-2024 | Jardiance, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.05 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $153.37 | 2019-2024 | Breztri |
| Sanofi-Aventis U.S. LLC | $104.42 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $99.50 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $89.98 | 2024-2025 | Cobenfy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.52 | 2020-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $60.08 | 2022-2023 | |
| Abbott Laboratories | $52.42 | 2021 | |
| Dexcom, INC. | $51.01 | 2023-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $43.30 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $43.10 | 2019-2020 | |
| Organon LLC | $40.99 | 2021-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.15 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $39.38 | 2019-2025 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $38.91 | 2019 | |
| Amarin Pharma, INC. | $38.29 | 2020 | |
| Pfizer INC. | $38.24 | 2020-2023 | |
| Corcept Therapeutics | $35.35 | 2022-2023 | Korlym |
| Astellas Pharma US INC | $34.79 | 2023 | Veozah |
| Exeltis, USA INC. | $34.35 | 2020 | |
| Therapeuticsmd, INC. | $33.72 | 2019-2020 | |
| Celgene Corporation | $33.21 | 2021 | |
| Inspire Medical Systems, INC. | $26.46 | 2025 | Inspire |
| Nevro Corp. | $22.51 | 2021 | |
| Ironshore Pharmaceuticals INC. | $18.36 | 2023 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $16.86 | 2024 | Rexulti |
| Gilead Sciences, INC. | $16.46 | 2019 | |
| Allergan, INC. | $16.38 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Medtronic USA, INC. | $14.92 | 2020 | |
| Amgen INC. | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Gulick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.